文献速递眼底病与葡萄膜炎

甲氨蝶呤与吗替麦考酚酯治疗葡萄膜炎的生活质量随机对照试验

Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis.
PubMed 文献 · Ophthalmology · 2021-03-04

该随机对照试验的二次分析纳入来自印度、美国、澳大利亚、沙特阿拉伯和墨西哥的非感染性葡萄膜炎患者,比较口服甲氨蝶呤与吗替麦考酚酯对健康相关和视相关生活质量的影响。结果显示,两种治疗在1年内均显著改善视相关和健康相关生活质量,且两组间无差异。

要点

  • 甲氨蝶呤或吗替麦考酚酯治疗非感染性葡萄膜炎均显著改善视相关生活质量。
  • 两种抗代谢药对健康相关生活质量的改善无组间差异。
  • 印度患者中通用与特定视功能量表评分高度相关。

核心结论

  • 接受甲氨蝶呤或吗替麦考酚酯治疗的葡萄膜炎患者,视相关和健康相关生活质量在1年内显著改善,且不因治疗分配而异。

研究设计与样本

  • 随机对照试验的二次分析,纳入来自印度、美国、澳大利亚、沙特阿拉伯和墨西哥的非感染性葡萄膜炎患者216例,随机接受口服甲氨蝶呤25 mg每周或吗替麦考酚酯1.5 g每日两次。

主要发现

  • 达到主要终点(6个月或6个月前治疗失败)的193例参与者中,NEI-VFQ评分较基线中位提高12.0分(IQR 1.0-26.1)。
  • SF-36v2 PCS较基线中位提高3.6分(IQR -1.4至14.9),MCS中位提高3.0分(IQR -3.7至11.9)。
  • NEI-VFQ、SF-36v2 PCS和MCS的改善均显著(P < 0.01)。
  • 线性混合模型显示各生活质量评估(NEI-VFQ、IND-VFQ、PCS、MCS)在治疗组间无差异(P > 0.05)。
  • 印度参与者中NEI-VFQ与IND-VFQ评分在基线、主要终点和次要终点的相关系数分别为0.87、0.80和0.90。

关键数值与推荐

  • 视相关生活质量采用NEI-VFQ和IND-VFQ评估,健康相关生活质量采用SF-36v2的PCS和MCS评估。
  • 评估时间点为基线、主要终点(6个月或6个月前治疗失败)和次要终点(12个月或6至12个月间治疗失败)。

临床怎么用

  • 对于接受甲氨蝶呤或吗替麦考酚酯治疗的非感染性葡萄膜炎患者,可预期生活质量的显著改善,两种药物对生活质量的影响相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate changes in health-related and vision-related quality of life (VRQoL) among patients with noninfectious uveitis who were treated with antimetabolites. DESIGN: Secondary analysis of a randomized controlled trial. PARTICIPANTS: Patients with noninfectious uveitis from India, the United States, Australia, Saudi Arabia, and Mexico. METHODS: From 2013 through 2017, 216 participants were randomized to receive 25 mg weekly oral methotrexate or 1.5 g twice daily oral mycophenolate mofetil. Median changes in quality of life (QoL) were measured using Wilcoxon signed-rank tests, and differences between treatment groups were measured using linear mixed models, adjusting for baseline QoL score, age, gender, and site. Among Indian patients, VRQoL scores from a general scale (the National Eye Institute Visual Function Questionnaire [NEI-VFQ]) and a culturally specific scale (the Indian Visual Function Questionnaire [IND-VFQ]) were compared using Pearson correlation tests. MAIN OUTCOME MEASURES: Vision-related QoL (NEI-VFQ and IND-VFQ) and health-related QoL (HRQoL; physical component score [PCS] and mental component score [MCS] of the Medical Outcomes Study 36-Item Short Form Survey [SF-36v2]) were measured at baseline, the primary end point (6 months or treatment failure before 6 months), and the secondary end point (12 months or treatment failure between 6 and 12 months). RESULTS: Among 193 participants who reached the primary end point, VRQoL increased from baseline by a median of 12.0 points (interquartile range [IQR], 1.0-26.1, NEI-VFQ scale), physical HRQoL increased by a median of 3.6 points (IQR, -1.4 to 14.9, PCS SF-36v2), and mental HRQoL increased by a median of 3.0 points (IQR, -3.7 to 11.9, MCS SF-36v2). These improvements in NEI-VFQ, SF-36v2 PCS, and SF-36v2 MCS scores all were significant (P < 0.01). The linear mixed models showed that QoL did not differ between treatment groups for each QoL assessment (NEI-VFQ, IND-VFQ, PCS SF-36v2, and MCS SF-36v2; P > 0.05 for all). The NEI-VFQ and IND-VFQ scores for Indian participants were correlated highly at baseline and the primary and secondary end points (correlation coefficients, 0.87, 0.80, and 0.90, respectively). CONCLUSIONS: Among patients treated with methotrexate or mycophenolate mofetil for uveitis, VRQoL and HRQoL improved significantly over the course of 1 year and did not differ by treatment allocation. These findings suggest that antimetabolites could improve overall patient well-being and daily functioning.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Kelly NK, Chattopadhyay A, Rathinam SR, et al. Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis. Ophthalmology. 2021. PMID: 33675850. doi:10.1016/j.ophtha.2021.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。